Screener
IDEAYA Biosciences, Inc. IDYA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by IDEAYA Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206357
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $157,522 | $112,825 |
| Short-term marketable securities | 513,679 | 526,563 |
| Prepaid expenses and other current assets | 18,346 | 21,366 |
| Contract assets | 6,560 | 5,973 |
| Total current assets | 696,107 | 666,727 |
| Restricted cash | 1,281 | 1,015 |
Item 1. Financial Statements (UNAUDITED).
FAQ
- What is IDEAYA Biosciences, Inc.'s cash & equivalents?
- IDEAYA Biosciences, Inc. (IDYA) reported cash & equivalents of $157.52M in Q1 2026.
- How has IDEAYA Biosciences, Inc.'s cash & equivalents changed year-over-year?
- IDEAYA Biosciences, Inc.'s cash & equivalents increased by 21.2% year-over-year, from $130M to $157.52M.
- What is the long-term trend for IDEAYA Biosciences, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), IDEAYA Biosciences, Inc.'s cash & equivalents has grown at a 9.4% compound annual growth rate (CAGR), from $72.04M to $112.83M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about IDEAYA Biosciences, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude